Fundraising Fox
Uniqure
Founded 1998 · 320 employees on LinkedIn · 4 known investors
Find your way into Uniqure
279 people in our graph share verified history with the Uniqure team — schools, employers, funds. One of them is your warm intro.
Raghu Madabushiunlockedknows Matthew Kapusta · together at Collins Stewart (overlapped)
knows the team · via Collins Stewart
×2knows the team · via Uniqure
×2knows the team · via AngioDynamics
×6knows the team · via Smith+Nephew
uniQure is a biotech company developing gene therapies for serious genetic diseases. The company's pipeline includes investigational treatments for conditions such as Huntington's disease, epilepsy, and Fabry disease.
Founders & leadership
MK
Matthew KapustaChief Executive OfficerMatthew Kapusta is Chief Executive Officer of uniQure, a biotech company developing gene therapies for serious genetic diseases. He joined the company as Chief Financial Officer in 2015 after two decades in the life sciences industry, with prior roles in corporate development at AngioDynamics, finance at Smith & Nephew Orthopaedics, and healthcare investment banking. Kapusta holds an MBA from NYU Stern and a BBA from University of Michigan's Ross School of Business.
Investors · 4
Founder mafia
4 people who came through Uniqure went on to found or lead other companies.
Frequently asked questions
- What does Uniqure do?
- uniQure is a biotech company developing gene therapies for serious genetic diseases. The company's pipeline includes investigational treatments for conditions such as Huntington's disease, epilepsy, and Fabry disease.
- Who are Uniqure's investors?
- Uniqure's investors include Advent Life Sciences, Foresite Capital, HEALTHCARE ROYALTY PARTNERS, Ridgeback Capital.